Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS: Bevacizumab with or without Erlotinib in advanced NSCLC
NCT00257608Phase 3Completed
- Sponsor
- Genentech
- Start
- Jan 2006
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Bevacizumab + Erlotinib with Bevacizumab + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 3 years. Started Jan 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00257608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00257608.